vs

Side-by-side financial comparison of Genie Energy Ltd. (GNE) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $138.3M, roughly 1.5× Genie Energy Ltd.). Genie Energy Ltd. runs the higher net margin — 4.9% vs -62.0%, a 66.9% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 23.6%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 14.8%).

Genie Energy Ltd. is an American energy company headquartered in Newark, New Jersey. It is a holding company comprising Genie Retail Energy, Genie Retail Energy International, Genie Energy Services, and Genie Energy Oil and Gas. Michael Stein is the Chief Executive Officer, Genie Energy Ltd.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

GNE vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.5× larger
RARE
$207.3M
$138.3M
GNE
Growing faster (revenue YoY)
RARE
RARE
+2.3% gap
RARE
25.9%
23.6%
GNE
Higher net margin
GNE
GNE
66.9% more per $
GNE
4.9%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
14.8%
GNE

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GNE
GNE
RARE
RARE
Revenue
$138.3M
$207.3M
Net Profit
$6.7M
$-128.6M
Gross Margin
21.7%
Operating Margin
5.0%
-54.7%
Net Margin
4.9%
-62.0%
Revenue YoY
23.6%
25.9%
Net Profit YoY
-33.9%
3.5%
EPS (diluted)
$0.26
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GNE
GNE
RARE
RARE
Q4 25
$207.3M
Q3 25
$138.3M
$159.9M
Q2 25
$105.3M
$166.5M
Q1 25
$136.8M
$139.3M
Q4 24
$102.9M
$164.6M
Q3 24
$111.9M
$139.5M
Q2 24
$90.7M
$147.0M
Q1 24
$119.7M
$108.8M
Net Profit
GNE
GNE
RARE
RARE
Q4 25
$-128.6M
Q3 25
$6.7M
$-180.4M
Q2 25
$2.8M
$-115.0M
Q1 25
$10.3M
$-151.1M
Q4 24
$-15.3M
$-133.2M
Q3 24
$10.2M
$-133.5M
Q2 24
$9.6M
$-131.6M
Q1 24
$8.1M
$-170.7M
Gross Margin
GNE
GNE
RARE
RARE
Q4 25
Q3 25
21.7%
Q2 25
22.3%
Q1 25
27.3%
Q4 24
32.5%
Q3 24
33.9%
Q2 24
36.8%
Q1 24
28.2%
Operating Margin
GNE
GNE
RARE
RARE
Q4 25
-54.7%
Q3 25
5.0%
-106.9%
Q2 25
1.9%
-64.8%
Q1 25
9.4%
-102.6%
Q4 24
-20.2%
-74.3%
Q3 24
10.4%
-94.6%
Q2 24
11.6%
-79.1%
Q1 24
8.2%
-151.9%
Net Margin
GNE
GNE
RARE
RARE
Q4 25
-62.0%
Q3 25
4.9%
-112.8%
Q2 25
2.7%
-69.0%
Q1 25
7.5%
-108.5%
Q4 24
-14.9%
-80.9%
Q3 24
9.1%
-95.7%
Q2 24
10.6%
-89.5%
Q1 24
6.8%
-156.8%
EPS (diluted)
GNE
GNE
RARE
RARE
Q4 25
$-1.28
Q3 25
$0.26
$-1.81
Q2 25
$0.11
$-1.17
Q1 25
$0.40
$-1.57
Q4 24
$-0.58
$-1.34
Q3 24
$0.38
$-1.40
Q2 24
$0.36
$-1.52
Q1 24
$0.30
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GNE
GNE
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$109.8M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.8M
$-80.0M
Total Assets
$394.1M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GNE
GNE
RARE
RARE
Q4 25
$421.0M
Q3 25
$109.8M
$202.5M
Q2 25
$106.0M
$176.3M
Q1 25
$118.3M
$127.1M
Q4 24
$110.1M
$174.0M
Q3 24
$141.8M
$150.6M
Q2 24
$126.8M
$480.7M
Q1 24
$106.9M
$112.3M
Stockholders' Equity
GNE
GNE
RARE
RARE
Q4 25
$-80.0M
Q3 25
$198.8M
$9.2M
Q2 25
$197.0M
$151.3M
Q1 25
$198.0M
$144.2M
Q4 24
$190.5M
$255.0M
Q3 24
$211.1M
$346.8M
Q2 24
$202.1M
$432.4M
Q1 24
$192.9M
$140.3M
Total Assets
GNE
GNE
RARE
RARE
Q4 25
$1.5B
Q3 25
$394.1M
$1.2B
Q2 25
$383.1M
$1.3B
Q1 25
$384.4M
$1.3B
Q4 24
$371.3M
$1.5B
Q3 24
$341.7M
$1.5B
Q2 24
$322.8M
$1.6B
Q1 24
$328.3M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GNE
GNE
RARE
RARE
Operating Cash FlowLast quarter
$13.9M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
2.07×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GNE
GNE
RARE
RARE
Q4 25
$-99.8M
Q3 25
$13.9M
$-91.4M
Q2 25
$1.1M
$-108.3M
Q1 25
$15.3M
$-166.5M
Q4 24
$13.0M
$-79.3M
Q3 24
$24.4M
$-67.0M
Q2 24
$20.4M
$-77.0M
Q1 24
$12.9M
$-190.7M
Free Cash Flow
GNE
GNE
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$13.6M
$-167.8M
Q4 24
$-79.5M
Q3 24
$21.9M
$-68.6M
Q2 24
$20.1M
$-79.0M
Q1 24
$11.7M
$-193.9M
FCF Margin
GNE
GNE
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
9.9%
-120.5%
Q4 24
-48.3%
Q3 24
19.6%
-49.2%
Q2 24
22.1%
-53.7%
Q1 24
9.8%
-178.2%
Capex Intensity
GNE
GNE
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.3%
1.0%
Q4 24
0.1%
Q3 24
2.2%
1.2%
Q2 24
0.4%
1.4%
Q1 24
1.0%
3.0%
Cash Conversion
GNE
GNE
RARE
RARE
Q4 25
Q3 25
2.07×
Q2 25
0.40×
Q1 25
1.49×
Q4 24
Q3 24
2.39×
Q2 24
2.12×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GNE
GNE

Sales Channel Directly To Consumer$108.8M79%
Sales Channel Through Intermediary$23.5M17%
Genie Renewables GREW$6.0M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons